Compare CMPX & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPX | ABCL |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.5M | 1.1B |
| IPO Year | 2020 | 2020 |
| Metric | CMPX | ABCL |
|---|---|---|
| Price | $1.94 | $4.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $15.83 | $8.40 |
| AVG Volume (30 Days) | ★ 7.9M | 4.0M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $934.41 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $1.61 | $1.94 |
| 52 Week High | $6.88 | $6.52 |
| Indicator | CMPX | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 19.32 | 69.11 |
| Support Level | N/A | $3.91 |
| Resistance Level | $3.74 | $4.76 |
| Average True Range (ATR) | 0.52 | 0.19 |
| MACD | -0.27 | 0.05 |
| Stochastic Oscillator | 1.91 | 78.71 |
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.